A Phase 1b/2 Study to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis.
Latest Information Update: 25 May 2026
At a glance
- Drugs NB 4746 (Primary)
- Indications Amyotrophic lateral sclerosis; Neurological disorders
- Focus Adverse reactions
- Sponsors Nura Bio
Most Recent Events
- 15 May 2026 Planned End Date changed from 1 Dec 2027 to 1 Feb 2028.
- 15 May 2026 Status changed from not yet recruiting to recruiting.
- 27 Jan 2026 Status changed from planning to not yet recruiting.